{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:45:11Z","timestamp":1753181111847},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis and are almost always fatal. The aim of this study was to evaluate the clinical outcome and toxicity of intraoperative electron beam radiation therapy (IOERT) in advanced and recurrent EOC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Forty-five women with EOC were treated with IOERT. Twenty-five patients had primary disease (PD) without distant metastasis at IOERT, and 20 patients had an isolated local recurrence (ILR) after surgery. All 45 patients in this series underwent optimal cytoreductive (\u2264 1 cm) surgery. The whole pelvic (WP) radiotherapy was intraoperatively delivered using 12 Mev electron beam; 43 patients received 18-20 Gy and two patients received 10 Gy. Thirty-three patients received postoperateive intraperitoneal (IP) chemotherapy, while seven patients received intravenous (IV) chemotherapy. Five patients refused concurrent chemotherapy. Overall survival (OS) rates were analyzed using the Kaplan-Meier method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Tumor recurrence and metastasis were observed in 16 patients (35.6%). Of those, 14 patients (31.1%) relapsed and two patients (4.4%) had distant metastasis alone. Eight of 25 (32%) local failures were observed in the PD group, as compared to 6\/20 (30%) in the ILR group (<jats:italic>P<\/jats:italic> = 0.885). Actuarial local control at five year follow-up was 31\/45 (68.9%). Seventeen of the total 45 (37.8%) patients died. Nine of 25 (36%) in the PD group died, as compared to 8 of 20 (40%) in the ILR group. The 5-year OS and disease-free survival (DFS) rates were 28\/45 (62.2%) and 25\/45 (55.6%), respectively. In the PD group, the 5-year OS and DFS rates were 16\/25 (64%) and 14\/25 (56%) (<jats:italic>P<\/jats:italic> &gt; 0.05, <jats:italic>vs<\/jats:italic>. the ILR group at 12\/20 and 11\/20, respectively). The OS and DFS in the IOERT plus IP group were 25\/33 (75.8%) and 23\/33 (69.7%), respectively, which were superior to the rates achieved with IOERT plus IV chemotherapy (<jats:italic>P<\/jats:italic> &lt; 0.05, 2\/7 and 1\/7, respectively). The major complication of IOERT was neuropathy. Five (11.1%) patients developed peripheral neurotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>IOERT may be feasible and effective as a boosting technique for advanced and recurrent ovarian cancer. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low risk of toxicity. Peripheral nerves in the IOERT field are dose-limiting structures requiring nerve protection policies or a dose compromise to ensure against severe neurological damage.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-439","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T18:49:32Z","timestamp":1319222972000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study"],"prefix":"10.1186","volume":"11","author":[{"given":"Ying","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"key":"2913_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009, 135: 1637-45. 10.1007\/s00432-009-0667-4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2913_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2007.07.079","volume":"107","author":"Y Nagai","year":"2007","unstructured":"Nagai Y, Inamine M, Hirakawa M, Kamiyama K, Ogawa K, Toita T, Murayama S, Aoki Y: Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007, 107: 469-73. 10.1016\/j.ygyno.2007.07.079.","journal-title":"Gynecol Oncol"},{"key":"2913_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1008240421028","volume":"8","author":"EA Eisenhauer","year":"1997","unstructured":"Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997, 8: 963-8. 10.1023\/A:1008240421028.","journal-title":"Ann Oncol"},{"key":"2913_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA: Cancer of the ovary. N Engl J Med. 2004, 351: 2519-29. 10.1056\/NEJMra041842.","journal-title":"N Engl J Med"},{"key":"2913_CR5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1200\/JCO.2002.20.5.1161","volume":"20","author":"RF Ozols","year":"2002","unstructured":"Ozols RF: Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002, 20: 1161-3.","journal-title":"J Clin Oncol"},{"key":"2913_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1525-1438.2003.13054.x","volume":"13","author":"G Cormio","year":"2003","unstructured":"Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L: Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003, 13: 125-9. 10.1046\/j.1525-1438.2003.13054.x.","journal-title":"Int J Gynecol Cancer"},{"key":"2913_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ygyno.2006.06.039","volume":"104","author":"P Blanchard","year":"2007","unstructured":"Blanchard P, Plantade A, Pag\u00e8s C, Afchain P, Louvet C, Tournigand C, de Gramont A: AIsolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol. 2007, 104: 41-5. 10.1016\/j.ygyno.2006.06.039.","journal-title":"Gynecol Oncol"},{"key":"2913_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/1097-0142(19940715)74:2<537::AID-CNCR2820740202>3.0.CO;2-R","volume":"74","author":"LL Gunderson","year":"1994","unstructured":"Gunderson LL: Rationale and results of intraoperative radiation therapy. Cancer. 1994, 74: 537-41. 10.1002\/1097-0142(19940715)74:2<537::AID-CNCR2820740202>3.0.CO;2-R.","journal-title":"Cancer"},{"key":"2913_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/1097-0142(19910715)68:2<278::AID-CNCR2820680211>3.0.CO;2-C","volume":"68","author":"CG Willett","year":"1991","unstructured":"Willett CG, Suit HD, Tepper JE, Mankin HJ, Convery K, Rosenberg AL: Intraoperative electron beam radiation therapy for retroperitoneal Soft tissue sarcoma. Cancer. 1991, 68: 278-83. 10.1002\/1097-0142(19910715)68:2<278::AID-CNCR2820680211>3.0.CO;2-C.","journal-title":"Cancer"},{"key":"2913_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0167-8140(03)00163-4","volume":"67","author":"I Azinovic","year":"2003","unstructured":"Azinovic I, Martinez Monge R, Javier Aristu J, Salgado E, Villafranca E, Fernandez Hidalgo O, Amillo S, San Julian M, Villas C, Manuel Aramend\u00eda J, Calvo FA: Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcoma of the extremities. Radiother Oncol. 2003, 67: 331-7. 10.1016\/S0167-8140(03)00163-4.","journal-title":"Radiother Oncol"},{"key":"2913_CR11","first-page":"155","volume":"88","author":"JB Dubois","year":"2001","unstructured":"Dubois JB: Intra-operative radiationtherapy in tumors of the digestive tract. BullCancer. 2001, 88: 155-62.","journal-title":"BullCancer"},{"key":"2913_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.canrad.2009.05.013","volume":"13","author":"JB Dubois","year":"2009","unstructured":"Dubois JB: Quel avenir pour la radioth\u00e9rapie per-op\u00e9ratoire?. Cancer Radiother. 2009, 13: 423-7.","journal-title":"Cancer Radiother"},{"key":"2913_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/978-3-642-71967-7_14","volume":"146","author":"MJ Eble","year":"1998","unstructured":"Eble MJ, Lehnert T, Herfarth C, Wannenmcher M: Intraoperative radiotherapy as adjuvant treatment for stageII\/III rectal carcinoma. Recent Results Cacer. 1998, 146: 152-60.","journal-title":"Recent Results Cacer"},{"key":"2913_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322\/canjclin.57.1.43.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2913_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322\/caac.20107.","journal-title":"CA Cancer J Clin"},{"key":"2913_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clon.2005.05.009","volume":"17","author":"AE Guppy","year":"2005","unstructured":"Guppy AE, Nathan PD, Rustin GJ: Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol). 2005, 17: 399-411. 10.1016\/j.clon.2005.05.009.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2913_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","volume":"17","author":"A Gadducci","year":"2007","unstructured":"Gadducci A, Cosio S: Surveillance procedures for patients treated for epithelial ovarian cancer: a review of literature. Int J Gynecol Cancer. 2007, 17: 21-31. 10.1111\/j.1525-1438.2007.00826.x.","journal-title":"Int J Gynecol Cancer"},{"key":"2913_CR18","first-page":"135","volume-title":"Int J Gynecol Obstet","author":"AP Heintz","year":"2003","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the ovary. Int J Gynecol Obstet. 2003, FIGO Annual Report Editorial Office, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy, 83: 135-66."},{"key":"2913_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3748\/wjg.14.1159","volume":"14","author":"HA Al-Shammaa","year":"2008","unstructured":"Al-Shammaa HA, Li Y, Yonemura Y: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008, 14: 1159-66. 10.3748\/wjg.14.1159.","journal-title":"World J Gastroenterol"},{"key":"2913_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1470-2045(04)01425-1","volume":"5","author":"O Glehen","year":"2004","unstructured":"Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004, 5: 219-28. 10.1016\/S1470-2045(04)01425-1.","journal-title":"Lancet Oncol"},{"key":"2913_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0360-3016(88)90255-6","volume":"14","author":"N Goldberg","year":"1988","unstructured":"Goldberg N, Peschel RE: Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Radiat Oncol Biol Phys. 1988, 14: 425-9. 10.1016\/0360-3016(88)90255-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2913_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijrobp.2004.09.010","volume":"62","author":"R Dinniwell","year":"2005","unstructured":"Dinniwell R, Lock M: Consolidative abdominopelvic radiotherapy after surgery and carboplatino\/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys. 2005, 62: 104-10. 10.1016\/j.ijrobp.2004.09.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2913_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archsurg.1993.01420160040005","volume":"128","author":"WF Sindelar","year":"1993","unstructured":"Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, Glatstein E: Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg. 1993, 128: 402-10.","journal-title":"Arch Surg"},{"key":"2913_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0167-8140(93)90004-R","volume":"28","author":"R Mart\u00ednez Monge","year":"1993","unstructured":"Mart\u00ednez Monge R, Jurado M, Azinovic I, Aristu JJ, Tangco E, Viera JC, Beri\u00e1n JM, Calvo FA: Intraoperative radiotherapy in recurrent gynecological cancer. Radiother Oncol. 1993, 28: 127-33. 10.1016\/0167-8140(93)90004-R.","journal-title":"Radiother Oncol"},{"key":"2913_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0929-6646(08)60202-8","volume":"107","author":"RJ Chen","year":"2008","unstructured":"Chen RJ, Chen KY, Chang TC, Sheu BC, Chow SN, Huang SC: Prognosis and Treatment of Squamous Cell Carcinoma from a Mature Cystic Teratoma of the Ovary. J Formos Med Assoc. 2008, 107: 857-68. 10.1016\/S0929-6646(08)60202-8.","journal-title":"J Formos Med Assoc"},{"key":"2913_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2009.06.021","volume":"115","author":"TC Krivak","year":"2009","unstructured":"Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL: A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol. 2009, 115: 81-5. 10.1016\/j.ygyno.2009.06.021.","journal-title":"Gynecol Oncol"},{"key":"2913_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ygyno.2008.11.021","volume":"112","author":"SN Chin","year":"2009","unstructured":"Chin SN, Pinto V, Rosen B, Oza A, Dodge J, Murphy J, Mackay H: Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol Oncol. 2009, 112: 450-4. 10.1016\/j.ygyno.2008.11.021.","journal-title":"Gynecol Oncol"},{"key":"2913_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00253116","volume":"1","author":"RB Jones","year":"1978","unstructured":"Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, De Vita VT: High volume intraperitoneal chemotherapy (\"belly bath\")for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978, 1: 161-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2913_CR29","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978, 62: 1-11.","journal-title":"Cancer Treat Rep"},{"key":"2913_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"MF Flessner","year":"1997","unstructured":"Flessner MF: Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997, 89: 480-7. 10.1093\/jnci\/89.7.480.","journal-title":"J Natl Cancer Inst"},{"key":"2913_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","volume":"100","author":"EL Trimble","year":"2006","unstructured":"Trimble EL, Christian MC: Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2006, 100: 3-4. 10.1016\/j.ygyno.2005.12.006.","journal-title":"Gynecol Oncol"},{"key":"2913_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1046\/j.1365-2168.2000.01538.x","volume":"87","author":"WP Ceelen","year":"2000","unstructured":"Ceelen WP, Hesse U, Hemptinne B, Pattyn P: Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra abdominal cancer. Br J Surg. 2000, 87: 1006-15. 10.1046\/j.1365-2168.2000.01538.x.","journal-title":"Br J Surg"},{"key":"2913_CR33","volume-title":"Practice Guidelines in Oncology","author":"NCCN","year":"2011","unstructured":"NCCN: Practice Guidelines in Oncology. 2011, NCCN, [http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp]"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-439\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T21:08:20Z","timestamp":1630616900000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2913"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-439","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]},"assertion":[{"value":"15 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"439"}}